Deficiency of the innate immune protein IFITM3 impairs phagocytosis and promotes autism-like behaviors in mice.

Scientists studied a protein called IFITM3 in mice to understand its role in autism. They found this protein helps clean up dying brain cells and reduces brain inflammation. When mice lacked this protein, they showed autism-like behaviors and had trouble clearing damaged brain cells. This research suggests IFITM3 might be important for brain health in autism and could lead to new treatments.

This preclinical study investigated the role of IFITM3, an immune protein, in autism spectrum disorder using mouse models. Researchers found that IFITM3 is crucial for clearing dying brain cells through a process called efferocytosis. When IFITM3 was depleted, mice showed impaired ability to clear apoptotic neurons and exhibited autism-like behaviors. The protein activates specific pathways that promote anti-inflammatory microglia proliferation, which helps resolve brain inflammation.

In dexamethasone-induced regression models, IFITM3 deficiency hindered tissue resolution and reduced clearance of dying neurons. The findings suggest IFITM3 could be a potential therapeutic target for managing neuroinflammation in autism spectrum disorder.

This preclinical research identifies IFITM3 as a potential therapeutic target for autism, particularly for managing neuroinflammation. However, translation to human applications requires further research including clinical trials to establish safety and efficacy.

Animal model findings may not translate directly to humans. Sample size not reported. Study type unclear from abstract. Limited detail on behavioral assessments used to determine autism-like behaviors in mice.

Interferon-induced transmembrane protein 3 (IFITM3) plays a protective role in autism spectrum disorder (ASD), a condition characterized by neuronal degradation and loss. The clearance of apoptotic neurons via efferocytosis activates resolution signaling pathways, driven by phagolysosome-mediated degradation of dying cells. We found that this degradation by phagolysosomal IFITM3 activates the Mer receptor tyrosine kinase/ musculoaponeurotic fibrosarcoma oncogene family B pathway, which drives the proliferation of anti-inflammatory microglia. This efferocytosis-induced microglial proliferation (EIMP) promotes the expansion of resolving microglia.

In dexamethasone-induced regression models, IFITM3 depletion inhibits EIMP, reduces apoptotic neuron clearance, and hinders tissue resolution. In conclusion, IFITM3 promotes apoptotic neuron clearance and EIMP in ASD, thereby mediating the resolution of inflammation. These findings suggest that IFITM3 could serve as a potential therapeutic target for modulating neuroinflammation in ASD.